Works citing this work

2 works

Work: Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

1. The Use of Nivolumab in Colorectal Cancer with Lynch Syndrome. A Case Report

   G. G. Khakimova, A. Tryakin, G.A. Khakimov Khakimov

   ArticleGenetic factors in colorectal cancerMalignant tumours20200 citations

   ABIABI:AkademIndex/openalex/2020.article.001794

2. Molecular mechanisms of colorectal cancer formation and their significance (literature review)

   Navruzov Sn, Behzod Navruzov, S. T. Rakhmonov +4

   ArticleGenetic factors in colorectal cancerSurgery and Oncology20240 citations

   ABIABI:AkademIndex/openalex/2024.article.004397